With ATVI trading around $82 we have some room to wiggle.
This confirms why I cast my lot with MSFT CEO Satya Nadella in the first place.
After buying in at a bargain price, the private equity firm is upping its bid for troubled Crown Resorts.
As M&A investments could hit $400 billion this year, watch for buys in health technology and data, biotech, pharma and medical devices.
A lot is riding on successfully pulling off the Warner Media deal.
The biotech sector looks ripe for staging a comeback, but a significant geopolitical event could throw the entire market for a loop.
I'm not saying get married to the stock, I'm saying that the idea could be a trade based on two possible catalysts.
Mirum Pharmaceuticals and TG Therapeutics are undervalued as stand-alone entities, but also would make easy and logical targets for a larger player.
The beaten-down name is finally lining up as an attractive value play.
In a market filled with charts without a clear stop, ORCL offers that.